

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**





FIG. I




FIG. 2





FIG. 3




FIG. 4





FIG. 6





FIG. 7





FIG. 8




FIG. 9




FIG. 10




FIG. II





FIG. 12



Formulation:

25mM Tris pH 7.2
60mM NaCl
1 mg/ml Arginine
5 mg/ml HSA
50 mg/ml Lactose




FIG. 13





FIG. 14



Formulation:

25mM Tris pH 7.2

60mM NaCl

1mg/ml Arginine

5mg/ml HSA

50mg/ml Trehalose

—■— -80°C Liquid

.....◄..... -20°C Liquid

--◆-- -20°C Lyoph

-●- Refrig. Lyoph

-▲- R.T. Lyoph

FIG. 15




FIG. 16A




FIG 16B




FIG. 16C




FIG. 16D




FIG. 17




FIG. 18






FIG. 19



CULTURE DAY

FIG. 20B



CULTURE DAY

FIG. 20A




FIG. 20D




FIG. 20C




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG 27




FIG. 28




FIG. 29




FIG. 30





FIG. 31

-B- DONER #1
-J- DONER #2
-H- DONER #3
-F- DONER #4
— DONER #5
— DONER #6
— DONER #7
— DONER #8
-M- DONER #9
— CONTROL
DONER




FIG. 32





FIG. 33



CROSS-LESS RETROVIRAL BACKBONE: pBA-5




FIG. 34




FIG. 35




FIG. 36




FIG. 37

2341 ArgGlyMetThrAlaLeuLeuLysValSerSerCysASPlysAsnThrGlyAspTyrTyr Seq ID No. 48
AGAGGCATGACCGCCTTACTGAAGGTTTCTAGTTGTGACCAAGAACACTGGTGAATTATTAC Seq ID No. 49
TCTCCGTACTGGCGGAATGACTTCCAAAGATCAACACTGTTCTTGTGACCACTAATAATG

2401 GluAspSerTyrGluAspIleSerAlaTyrLeuLeuSerLysAsnAsnAlaIleGluPro
GAGGACAGTTATGAAGATATTTCAGCATACTTGCTGAGTAAAAACAATGCCATTGAACCA
CTCCTGTCAATACTTCTATAAAGTCGATGAACGACTCATTTTGTACGGTAACCTGGT

<-----N-terminus of beta domain----->

2461 ArgSerPheSerGlnAsnSerArgHisProSerThrArgGlnLysGlnPheAsnAlaThr
AGAAGCTTCTCCAGAAATCTAGACACCCTAGCACCTAGGCAAAAGCAATTTAATGCCACC
TCTTCGAAGAGGGTCTTAAGATCTGTGGGATCGTGATCCGTTTTCGTTAAATTACGGTGG

2463 HIND3, 2475 ECOR1, 2479 XBA1,

<-- IGA hinge ---><-- C-term. beta domain -->


2521 ProProThrProProThrProProValLeuLysArgHisGlnArgGluIleThrArgThr
CCTCCTACACCAACCAACCCACCAAGTACTGAACGCGCATCAACGGGAATAACTCGTACT
GGAAGATGTGGTGGTTGGGGTGGTCAATGACTTTCGGGTAGTTGCCCTTATTGAGCATGA

2544 SCA1,

2581 ThrLeuGlnSerAspGlnGluGluIleAspTyrAspAspThrIleSerValGluMetLys
ACTCTTCAGTCTGATCAAGAGGAATAATGACTATGATGATACCATATCAGTTGAATGAAG
TGAGAAGTCAGACTAGTTCCTCTTAACGTACTACTACTATGTAATAGTCAACTTACTTC

2592 BCL1,

FIG. 38





Seq ID No. 75 AsnSerArgHisProSer 11 12 13 14 15 16 17 18 19 20 21
F8-14E ginasnProProValleuLysArgHisGlnArgGluIleThr
Seq ID No. 77 2 AATTCGCGACACCCCTAGC CAAAACCCACCAGTCTTGAACACGCCATCAACGGGGAATAACG
Seq ID No. 79 GCGCTGTGGGATCGGTTTGGGTGTCAGAAC TTTGCGGTAGTTGCCCTTAATTGC
F8-15E
Seq ID No. 81 ArgThrLeuGlnSerAsp
F8-16E
Seq ID No. 82 62 CGTACTCTTCAGTCT
Seq ID No. 83 GCATGAGGAAGTCAGACTAG
F8-17E ^
76 BCL1,
^ E^OR1, 5 NRU1, 59 MLU1,
region NRU1 MLU1 BCL1
begin 80K

FIG. 39




FIG. 40A




FIG. 40B

Linkers for pSVF8-500B

end 92 19aa C terminal
to thrombin cleavage at 740

mutant
wild type

SerArgHisProSerThrArgGlnLysGlnPheAsnAlaThrProProValLeuLysArg Seq ID No. 50
TCGGACACCCCTAGCACTAGGCAAAAGCAATTAAATGCCACCCACCAAGTCTGAACGC Seq ID No. 51
AGCGCTGTGGATCGTGATCCGTTTCGTTAAATTACGGTGGGTGGTCATGACTTTGCG
(TT)
NRU1
(CT)

Start 80K
HisGlnArgGluLeuThrArg
CATCAACGGGAAATAACGGGT
GTAGTTGCCCTTATTGCGCA

MLU1
9aa N terminal to 80K

FIG. 41

